Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-12-21 Share Issue/Capital Cha…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Cleansing Notice 2 pages 669.4KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares following the exercise of performance rights. It is a regulatory announcement about a share issue event, specifically notifying compliance with disclosure requirements under the Corporations Act. The document does not contain financial statements, management discussion, or detailed financial data. It is not a full report but a formal regulatory notice about a capital transaction. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is 4607 characters, which is consistent with a brief regulatory announcement rather than a full report.
2025-12-21 English
Appendix 3Y - Paul Anderson 2 pages 226.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options held before and after the change, nature of the interest, and dates of changes. This type of document is a formal notification of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, audit information, or meeting materials. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2025-12-21 English
Orthocell Hits US Milestone - 100 Remplir Units Sold. 3 pages 682.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing Orthocell's achievement of a sales milestone for its product Remplir™ in the US market. It focuses on commercial progress, market adoption, distributor networks, and future growth plans. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about business progress and market adoption rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. The content is consistent with a Capital/Financing Update or general business progress announcement. However, since it primarily reports on sales milestones and market adoption rather than fundraising or capital structure changes, the best fit is a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2025-12-17 English
Remplir Regulatory Application for US$750m EU-UK Market 3 pages 667.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Orthocell Limited regarding the submission of a regulatory application for commercial distribution of a medical product (Remplir™) in the EU and UK markets. It discusses regulatory approval timelines, market size, clinical study results, and the company's go-to-market strategy. The content is focused on a regulatory and commercial update rather than financial results, management changes, or detailed financial data. The document is approximately 9,532 characters, which is relatively short and reads as a formal announcement rather than a detailed report. There is no indication of financial statements, audit information, or earnings data. It is not a report publication announcement since it contains substantive information about the regulatory submission and market strategy. The document fits best as a Regulatory Filings (RNS) type, which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2025-12-14 English
First Commercial Sales of Remplir Achieved in Hong Kong 3 pages 270.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the first commercial sales of a product (Remplir™) in Hong Kong and updates on the company's global commercialisation strategy. It includes forward-looking statements, market information, and operational updates but does not contain financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about sales milestones and market expansion rather than a financial report or regulatory filing. Therefore, it fits best into the category of a Capital/Financing Update (CAP) as it relates to commercial progress and company growth strategy updates.
2025-12-09 English
Notification regarding unquoted securities - OCC 8 pages 22.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities under an employee incentive scheme. It includes specifics such as the number of securities issued, issue dates, and references to ASX listing rules. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a share issue event, specifically unquoted securities issued under an employee incentive plan. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other categories. Therefore, the appropriate classification is SHA (Share Issue/Capital Change). The document length (7542 characters) and content confirm it is a full notification, not just a brief announcement or a report publication announcement.
2025-11-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.